Abstract
Introduction. The results of an analysis of the frequency of occurrence, the dependence of the clinical picture on the duration of the disease and the results of drug correction of bacterial overgrowth syndrome (SIBO) that develops in patients taking proton pump inhibitors (PPIs) for a long time as a prophylaxis of erosive and ulcerative lesions while taking acetylsalicylic acid (ASA).
Material and methods. The study group included 17 patients with cardiovascular pathology, who took ASA drugs for a long time in combination with PPIs. All patients showed an increase in the hydrogen gradient in the exhaled air according to the hydrogen breath test (HBT). In order to correct the pathological condition, all patients received rifaximin (Alfa Normix 200 mg, Alfa Wassermann S.p.A, Italy) at a dose of 800 mg / day for 7 days.
Results. On the 8th day of therapy, positive dynamics was noted in the form of a decrease in the intensity of clinical manifestations and the normalization of the results of НВТ.
Conclusion. The severity of the clinical manifestations of SIBO, as well as the degree of increase in the hydrogen breath test, depend on the duration of the PPI intake. The drug Rifaximin is effective in the therapy of SIBO.
References
- Назаров Н.С., Логинов В.А. Опыт диагностики синдрома избыточного бактериального роста у пациентов с сердечно-сосудистой патологией. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2020; 21 (1): 51–5. DOI: 10.24022/1810-0694-2020-21-1-51-55
- Ardatskaya M.D. Excessive bacterial growth syndrome in smal intestine up-to-date diagnostics methods and approaches to therapeutic correction. Medical Councilium. 2016; 14: 88–95 (in Russ.). DOI: 10.24022/1810-0694-2020-21-1-51-55
- Kashukh E.A., Poluektova E.A., Kudryavtseva A.V., Krasnov G.S., Kazey V.I., Sobolev P.D. et al. Effect of Rifaximin and a multi-strain probiotic on the intestinal microbiome and cardiovascular risk indicators in patients with coronary heart disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019; 29 (4): 38–49 (in Russ.).
- Minushkin O.N., Maslovskiy L.V., Topchiy T.B., Skibina Yu.S., Evsikov A.E. Approaches to the treatment of patients with the syndrome of excessive bacterial growth in the small intestine, which developed in connection with the pathology of the upper gastrointestinal tract. Lechashchiy Vrach (Attending Physician). 2017; 2: 40–4 (in Russ.).
- Yakovenko E.P., Agafonova N.A., Yakovenko A.V., Ivanov A.N., Soluyanova I.P. Antibiotics, prebiotics, probiotics, metabiotics in the terapy of small intestinal bacterial overgrowth. Dificult Patient. 2018; 16 (4): 16–22 (in Russ.).
- Krajicek E.J., Hansel S.L. MSb small intestinal bacterial overgrowth. Mayo Clin. Proc. 2016; 91 (12): 1828–33. DOI: 10.1016/j.mayocp.2016.07.025
- Lombardo L., Foti M., Ruggia O., Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 2010; 8 (6): 504–8. DOI: 10.1016/j.cgh. 2009.12.022
About the authors
- Nikita S. Nazarov, Cand. Med. Sci., Researcher; ORCID
- Vladimir A. Loginov, Cand. Med. Sci., Gastroenterologist; ORCID
